Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A US decision to award a set of key patents related to CRISPR–Cas9 gene editing to the Broad Institute could spell the end for a long-running dispute over inventorship with the University of California and the University of Vienna.
A ruling by the US Patent and Trademark Office (USPTO) Appeals Board resolves a conflict over rights to the foundational CRISPR–Cas9 genome editing technology in eukaryotic cells. It may also give the Broad Institute, and the companies licensing this technology, an advantage in intellectual property (IP) negotiations.